Narratives are currently in beta
- In 5 years, the company should still be thriving, entering new markets and expanding in existing ones. Positive passage of the third stage of testing of a new cardiac marker could help. Due to the nature of this product, it will be difficult to manufacture it in new markets, the company plans to cooperate with any of the major players in the US market, and in the context of Poland to develop its own facilities.
- I think EPS growth will be about 20% on average per year, which at the current price in 5 years should yield about PLN 500 per share. However, this calculation assumes that the Price/Earnings ratio will then be 22 (currently 20.3).
How well do narratives help inform your perspective?
Disclaimer
The user Phetuvov has a position in WSE:SNT. Simply Wall St has no position in any of the companies mentioned. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives